{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:13:57Z","timestamp":1784888037715,"version":"3.55.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n            <jats:title>Background and aims:<\/jats:title>\n            <jats:p>To assess the characteristics, care, treatment response, and outcomes of primary biliary cholangitis (PBC) patients recently followed-up by hepato-gastroenterologists in various French and Belgian healthcare settings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This retrospective cohort study included patients with PBC who recently visited 79 hepato-gastroenterologists in France and Belgium. Data were collected at the time of diagnosis and at last visit and were compared according to biochemical response (BR) to ursodeoxycholic acid (UDCA) (BR), using Paris I\u2013II criteria, and clinical outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 436 patients (mean age at diagnosis 57 years, 88% females, median follow-up 5.2 years) were included. Liver biopsy, transient elastography, or none of these two procedures were performed at baseline in 216 (50%), 194 (45%), and 107 (25%) patients, respectively. Late-stage disease (histological stage III or IV, or transient elastography \u22659.6 kPa, or bilirubin &gt;17 \u00b5M and albumin &lt;35 g\/L, or platelets &lt;150.000\/\u00b5l, or unequivocal signs of portal hypertension or cirrhosis) was reported in 37% of patients. UDCA was taken by 95% of patients (27% had suboptimal dosage). Inadequate BR was observed in 37% of patients. Clinicians overestimated disease control. Liver-related complications occurred in 9% of patients. Bilirubin and albumin independently predicted inadequate BR; advanced disease stage and inadequate BR independently predicted complications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Recently followed-up French and Belgian patients with PBC had homogeneous management. Late stage at diagnosis and inadequate BR were reported in around 40% of patients. Disease control was frequently overestimated by clinicians. Disease stage and BR were the main prognostic factors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000002011","type":"journal-article","created":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T20:03:14Z","timestamp":1606680194000},"page":"e197-e205","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Management of primary biliary cholangitis: results from a large real-life observational study in France and Belgium"],"prefix":"10.1097","volume":"33","author":[{"given":"Alexandre","family":"Pariente","sequence":"first","affiliation":[{"name":"Calotis, Mauvezin d\u2019Armagnac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chazouilleres","sequence":"additional","affiliation":[{"name":"Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, French Network for Rare Liver Diseases in Adults and Children (FILFOIE), European Reference Network Rare-Liver, Saint-Antoine Hospital, Assistance Publique \u2013 H\u00f4pitaux de Paris (APHP), Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Causse","sequence":"additional","affiliation":[{"name":"Hepatology and Gastroenterology Unit, Centre Hospitalier R\u00e9gional, Orl\u00e9ans La-Source, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Hanslik","sequence":"additional","affiliation":[{"name":"Montpellier Center for Liver and Digestive System Diseases, Montpellier, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Arpurt","sequence":"additional","affiliation":[{"name":"Hepatology and Gastroenterology Unit, Centre Hospitalier, Avignon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Henrion","sequence":"additional","affiliation":[{"name":"Hepatology and Gastroenterology Unit, H\u00f4pital de Jolimont, La Louvi\u00e8re, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Rosa","sequence":"additional","affiliation":[{"name":"Hepatology and Gastroenterology Unit, Centre Hospitalier Intercommunal, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Renou","sequence":"additional","affiliation":[{"name":"Hepatology and Gastroenterology Unit, Centre Hospitalier d\u2019 Hy\u00e8res, Hy\u00e8res, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Garioud","sequence":"additional","affiliation":[{"name":"Hepatology and Gastroenterology Unit, Centre Hospitalier de Creil, Creil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Corpechot","sequence":"additional","affiliation":[{"name":"Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, French Network for Rare Liver Diseases in Adults and Children (FILFOIE), European Reference Network Rare-Liver, Saint-Antoine Hospital, Assistance Publique \u2013 H\u00f4pitaux de Paris (APHP), Sorbonne University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of DESCRIPT and DESCRIPT Study Groups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"R1-20240821","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hep.28859","article-title":"Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis.","volume":"65","author":"Dahlqvist","year":"2017","journal-title":"Hepatology"},{"key":"R2-20240821","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis.","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J Hepatol"},{"key":"R3-20240821","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid.","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"key":"R4-20240821","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"R5-20240821","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"R6-20240821","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.","volume":"28","author":"Chazouill\u00e8res","year":"1998","journal-title":"Hepatology"},{"key":"R7-20240821","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"R8-20240821","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy.","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"R9-20240821","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"R10-20240821","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","article-title":"Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment.","volume":"16","author":"Lu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R11-20240821","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.14309\/ajg.0000000000000290","article-title":"Validation of risk scoring systems in ursodeoxycholic acid-treated patients with primary biliary cholangitis.","volume":"114","author":"Efe","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"R12-20240821","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/00365521.2019.1606931","article-title":"Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.","volume":"54","author":"\u00d6rnolfsson","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"R13-20240821","first-page":"1","article-title":"CLEO-AIGO PBC study group. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy.","volume":"28","author":"Vespasiani-Gentilucci","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"R14-20240821","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0168-8278(99)80136-6","article-title":"Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial.","volume":"30","author":"Angulo","year":"1999","journal-title":"J Hepatol"},{"key":"R15-20240821","first-page":"240","article-title":"How the concept of biochemical response influenced the management of primary biliary cholangitis over time.","volume":"74","author":"Lammers","year":"2016","journal-title":"Neth J Med"},{"key":"R16-20240821","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid.","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"R17-20240821","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis.","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"R18-20240821","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1007\/s10620-019-5457-5","article-title":"Treatment of fatigue in primary biliary cholangitis: a systematic review and meta-analysis.","volume":"64","author":"Lee","year":"2019","journal-title":"Dig Dis Sci"},{"key":"R19-20240821","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.cgh.2018.12.007","article-title":"Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom.","volume":"17","author":"Hegade","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R20-20240821","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome.","volume":"113","author":"Harms","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"R21-20240821","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"key":"R22-20240821","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0168-8278(94)80111-8","article-title":"Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis.","volume":"21","author":"Leuschner","year":"1994","journal-title":"J Hepatol"},{"key":"R23-20240821","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis.","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R24-20240821","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.gcb.2010.07.018","article-title":"The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis.","volume":"35","author":"Kuiper","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T22:07:08Z","timestamp":1724364428000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":24,"journal-issue":{"issue":"1S","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002011","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,30]]}}}